Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2024-11-20 00:00:00 ET · period of report 2024-11-19 · accession 0001104659-24-120876 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-20 | 2024-11-19 | NVCT | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $4.99 | +2,000 | 1.51M | +0.1% | +$9,980 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-19 | P | A | 2,000 | $4.99 | 1,506,319 | D | — | — | (F1) Reflects the weighted average purchase price. The range of prices for the shares purchased was $4.98 to $4.99. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. (F2) Includes 353,399 shares of restricted stock. |